Heteromers of μ‐δ opioid receptors: new pharmacology and novel therapeutic possibilities
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Several studies suggest that heteromerization between μ (MOP) and δ (DOP) opioid receptors modulates the signalling properties of the individual receptors. For example, whereas activation of MOP receptors by an agonist induces G protein‐mediated signalling, the same agonist induces β‐arrestin‐mediated signalling in the context of the MOP‐D OP receptor heteromer. Moreover, heteromer‐mediated signalling is allosterically modulated by a combination of MOP and DOP receptor ligands. This has implications in analgesia given that morphine‐induced antinociception can be potentiated by DOP receptor ligands. Recently reagents selectively targeting the MOP‐D OP receptor heteromer such as bivalent ligands, antibodies or membrane permeable peptides have been generated; these reagents are enabling studies to elucidate the contribution of endogenously expressed heteromers to analgesia as well as to the development of side‐effects associated with chronic opioid use. Recent advances in drug screening technology have led to the identification of a MOP‐D OP receptor heteromer‐biased agonist that activates both G protein‐mediated and β‐arrestin‐mediated signalling. Moreover, this heteromer‐biased agonist exhibits potent antinociceptive activity but with reduced side‐effects, suggesting that ligands targeting the MOP‐D OP receptor heteromer form a basis for the development of novel therapeutics for the treatment of pain. In this review, we summarize findings regarding the biological and functional characteristics of the MOP‐D OP receptor heteromer and the in vitro and in vivo properties of heteromer‐selective ligands. Linked Articles: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 2×
“In general, the number of new drugs approved by the FDA is around 20 per year, and around 10 can be developed by large pharmaceutical companies, of which 20–30% would be considered ‘first-class’ medicines (Paul et al., 2010).”
InfluentialFredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., et al. (1996) · Nature · doi:10.1038/383819a0 · Cited by 1,722 · cited 1×
“Also, studies with mice lacking MOP receptors showed that they exhibited reduced antinociception to DOP receptor-selective agonists compared with wild-type controls (Matthes et al., 1996; British Journal of Pharmacology (2015) 172 375–387 377 1998).”
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364 · cited 2×
“…created the Molecular Libraries Initiative and the Molecular Libraries Screening Center Network to facilitate the establish- ment of translational and chemical screening programs at academic screening centers (http://www.slas.org/screening Facilities/facilityList.cfm) (Macarron et al., 2011).”
Waldhoer, M., Bartlett, S. E., & Whistler, J. L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073940 · Cited by 740
Cell surface targeting of μ-δ opioid receptor heterodimers by RTP4
Décaillot, F. M., Rozenfeld, R., Gupta, A., & Devi, L. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804106105 · Cited by 152
Self-citation
Cited by
Endogenous and Exogenous Opioids in Pain
Corder, G., Castro, D. C., Bruchas, M. R., & Scherrer, G. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-061522 · Cited by 502
Opioid-induced hyperalgesia: Cellular and molecular mechanisms
Roeckel, L.-A., Le Coz, G.-M., Gavériaux-Ruff, C., & Simonin, F. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.06.029 · Cited by 388
Opioid Analgesia and Opioid-Induced Adverse Effects: A Review
Paul, A. K., Smith, C. M., Rahmatullah, M., Nissapatorn, V., Wilairatana, P., Spetea, M., Gueven, N., & Dietis, N. (2021) · Pharmaceuticals · doi:10.3390/ph14111091 · Cited by 300
Misuse of Novel Synthetic Opioids: A Deadly New Trend
Prekupec, M. P., Mansky, P. A., & Baumann, M. H. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000324 · Cited by 283
G protein-coupled receptor heteromers
Gomes, I., Ayoub, M. A., Fujita, W., Jaeger, W. C., Pfleger, K. D. G., & Devi, L. A. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135952 · Cited by 262
Self-citationPanossian, A., Seo, E.-J., & Efferth, T. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.204 · Cited by 127
G-protein–coupled receptors are dynamic regulators of digestion and targets for digestive diseases
Canals, M., Poole, D. P., Veldhuis, N. A., Schmidt, B. L., & Bunnett, N. W. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.266 · Cited by 35
Metadata
- Authors
- Fujita, W., Gomes, I., & Devi, L. A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-07
- Volume
- 172
- Issue
- 2
- Pages
- 375-387
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1914290984
- Cited by
- 98
- References
- 6
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.